<DOC>
	<DOCNO>NCT00760955</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness TAK-583 , daily ( QD ) , treatment neuropathy cause diabetes mellitus .</brief_summary>
	<brief_title>Efficacy Safety TAK-583 Subjects With Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description>Diabetic polyneuropathy frequent complication individual type 1 2 diabetes mellitus , result progressive functional structural deficit somatic autonomic nerve . Diabetic polyneuropathy characterize degenerative change nerve fiber result progressive functional structural deficit somatic autonomic nerve . TAK-583 synthetic compound currently development treatment diabetic polyneuropathy . The purpose study evaluate safety efficacy TAK-583 treatment mild moderate diabetic polyneuropathy subject type 1 type 2 diabetes mellitus . Study participation anticipate 8 month .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Female subject must postmenopausal status post document hysterectomy bilateral oophorectomy . Has fast clinical laboratory evaluation within normal reference range test laboratory , , result must deem clinically significant investigator prior randomization . Has Type 1 type 2 diabetes , define World Health Organization Criteria . Has mild Moderate Diabetic Peripheral Neuropathy define : Confirmed abnormality least two nerve conduction velocity parameter define Neurological Core Laboratory . Sural sensory nerve potential amplitude great equal 1 Î¼V ( microvolt ) . Has glycosylated hemoglobin less equal 10 % . Is stable pain medication least 3 week prior randomization , applicable . Has glomerular filtration rate calculate Modification Diet Renal Disease great equal 45 mL/min/ body surface area . Spot albumin/creatinine ratio le 300 mg/g creatinine 33.9 mg/mmol creatinine . Has acceptable clinical laboratory test result define : Hemoglobin Greater equal 9.0 g/dL 5.58 mmol/L Thyroid stimulate hormone Within normal limit Free T4 index Within normal limit B12 level Within normal limit Is willing follow American Diabetes Association similar recommend dietary regimen . Exclusion Criteria Individuals history neuropathy due cause diabetes alcohol abuse , liver renal disease , uremia , toxic exposure , genetic factor , autoimmune disorder , inflammatory demyelinating disease , monoclonal gammopathy ; endocrine , metabolic nutritional disorder . Has clinical electrophysiologic evidence bilateral carpal tunnel syndrome . Has significant skin abnormality ulcerative change low extremity may interfere performance study related procedure . Has body mass index great 45 kg/m2 . Participants uncontrolled hypertension systolic blood pressure great 160 mm Hg diastolic blood pressure great 95 mm Hg . Has history myocardial infarction , coronary angioplasty bypass graft , unstable angina pectoris , transient ischemic attack , clinically significant abnormal electrocardiogram , New York Heart Association Functional Classification III IV , document cerebrovascular accident . Has mark baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval great 450 millisecond ) . Has history additional risk factor Torsades de pointes . Is required take intend continue take disallowed medication , prescription medication , herbal treatment overthe counter medication may interfere evaluation study medication , include : Medications prolong QT/QTc interval . Lipoic acid . Linolenic acid ( primrose oil ) . Inositol . Topiramate . AcetylLCarnitine . Nerve growth factor . Capsaicin . CYP3A4 inhibitor ( amiodarone , diltiazem , Verapamil ) HIV protease inhibitor Itraconazole Ketoconazole macrolide antibiotic CYP 3A4 inducer Has alanine aminotransferase level great 1.5 time upper limit normal , active liver disease jaundice Total bilirubin great 1.2 time upper limit normal . Has 12hour urinary cortisol test great 264 nmol/night ( 95.6 mcg/night ) screening . Has clinically significant ( determined investigator ) unstable : pulmonary , gastrointestinal , hepatic , hematologic , musculoskeletal , osteoporosis , osteopenia , endocrine ( diabetes mellitus stably treat hypothyroidism ) diseases . Has previous history cancer remission least 5 year prior first dose study drug . Has serious disease condition screen randomization might affect life expectancy make difficult successfully manage follow subject accord protocol . Has history drug abuse history alcohol abuse within past 2 year . Has know hypersensitivity compound relate TAK583 . Is currently participate another investigational study participate investigational study within past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Asymmetric Diabetic Proximal Motor Neuropathy</keyword>
	<keyword>Diabetic Amyotrophy</keyword>
	<keyword>Diabetic Autonomic Neuropathy</keyword>
	<keyword>Diabetic Polyneuropathy</keyword>
	<keyword>Neuralgia , Diabetic</keyword>
	<keyword>Symmetric Diabetic Proximal Motor Neuropathy</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>